Dr. Dawn opens with groundbreaking results from Vertex Pharmaceuticals' stem cell treatment for severe type 1 diabetes. The experimental therapy, Zimislecel, converts stem cells into pancreatic islet cells and infuses them into patients. In a 12-person study, 10 patients no longer need insulin after one year. The cells migrated to the liver and began producing insulin in response to glucose levels. Patients with hypoglycemic unawareness saw complete elimination of dangerous episodes after three months. However, patients must take lifelong immunosuppressive drugs to prevent rejection. The research represents 25 years of work by Harvard's Doug Melton.

A caller asks about Keytruda treatment for melanoma. Dr. Dawn explains it's an immunotherapy drug targeting programmed death receptors that cancer cells hijack to evade immune response. The drug can cause serious immune overreactions but is standard for metastatic melanoma. Treatment protocols depend on cancer staging. For young patients with decades to lose, aggressive treatment is often justified despite risks.

An email about morning arthritis pain leads to chronotherapy research discussion. Macrophages have energy levels that peak in the morning when inflammasome activation is quicker and more robust, explaining why arthritis pain is worst after overnight rest. Treatment timing could optimize anti-inflammatory medications by taking them at bedtime.

Another email about eye irritation prompts diagnostic discussion. Dr. Dawn recommends examining for bacterial blepharitis before assuming food allergies and testing antihistamine drops. For elimination diets, common allergens include wheat, dairy, corn, soy, and peanuts. However, without other symptoms, food allergies are unlikely causes of isolated eye problems.

Dr. Dawn explores advancing CAR-T cell therapy using RNA technology. Traditional therapy costs up to $500,000 per patient requiring lab reprogramming. New RNA-containing nanoparticles temporarily create antigen receptors for about one week. Mouse studies eliminated detectable tumors at highest doses. While effects are temporary, this could dramatically reduce costs and complexity.

She discusses DNA forensics evolution from O.J. trial era to current technologies. New paleogenomics technology can analyze fragmented DNA from hair, previously considered unusable. Mitochondrial DNA analysis can definitively exonerate suspects. This led to Charles Fane's release after 17 years on death row when hair evidence proved innocence and identified the actual perpetrator.

Dr. Dawn introduces Barrett's esophagus screening replacing invasive endoscopy. Patients swallow a capsule containing a compressed sponge that expands in the stomach and is pulled out via string, collecting esophageal cells. The test identifies abnormalities with 100-fold increased cancer risk when positive and 98% accuracy when negative, allowing targeted endoscopy only for high-risk patients.

She concludes discussing body composition analysis superiority over BMI. Studies found overweight BMI showed 3.6 times higher heart disease risk, while large waist circumference showed four times higher risk. However, BMI had no significant relationship with overall mortality. Dr. Dawn advocates for bioimpedance analysis devices to measure body fat percentage and track muscle loss.